Results 21 to 30 of about 68,113 (243)

Lamprey Variable Lymphocyte Receptors Mediate Complement-Dependent Cytotoxicity [PDF]

The Journal of Immunology, 2013
Abstract An alternative adaptive-immune system is present in the most basal vertebrates—lampreys and hagfish—the only surviving jawless vertebrates. These eel-like fish use leucine-rich repeat–based receptors for Ag recognition instead of the Ig-based receptors used in jawed vertebrates.
Fenfang, Wu, Liyong, Chen, Xin, Liu, Huaying, Wang, Peng, Su, Yinglun, Han, Bo, Feng, Xu, Qiao, Jing, Zhao, Ning, Ma, Huijie, Liu, Zhen, Zheng, Qingwei, Li   +12 more
openaire   +2 more sources

Endovascular trophoblast expresses CD59 to evade complement-dependent cytotoxicity [PDF]

Molecular and Cellular Endocrinology, 2019
In the human placenta, extravillous trophoblasts (EVTs) invade maternal decidual tissues (interstitial trophoblasts) and maternal spiral arteries (endovascular trophoblasts). Although endovascular trophoblasts are directly exposed to maternal blood containing complement components, they are not eliminated by complement-dependent cytotoxicity (CDC).
Masashi Ueda, Yukiyasu Sato, Akihito Horie, Hirohiko Tani, Yumiko Miyazaki, Asuka Okunomiya, Hisanori Matsumoto, Junzo Hamanishi, Eiji Kondoh, Masaki Mandai   +9 more
openaire   +2 more sources

CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering

Haematologica, 2019
CD20 monoclonal antibody therapies have significantly improved the outlook for patients with B-cell malignancies. However, many patients acquire resistance, demonstrating the need for new and improved drugs.
Simone C. Oostindie, Hilma J. van der Horst, Margaret A. Lindorfer, Erika M. Cook, Jillian C. Tupitza, Clive S. Zent, Richard Burack, Karl R. VanDerMeid, Kristin Strumane, Martine E. D. Chamuleau, Tuna Mutis, Rob N. de Jong, Janine Schuurman, Esther C. W. Breij, Frank J. Beurskens, Paul W. H. I. Parren, Ronald P. Taylor   +16 more
doaj   +1 more source

Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab

Haematologica, 2011
Background In our efforts to develop novel effective treatment regimens for multiple myeloma we evaluated the potential benefits of combining the immunomodulatory drug lenalidomide with daratumumab.
Michael. S. van der Veer, Michel de Weers, Berris van Kessel, Joost M. Bakker, Shulamiet Wittebol, Paul W.H.I. Parren, Henk M. Lokhorst, Tuna Mutis   +7 more
doaj   +1 more source

The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden

Haematologica, 2011
Background CD20 monoclonal antibodies are widely used in clinical practice. Antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity and direct cell death have been suggested to be important effector functions for CD20 antibodies ...
Peter Boross, J.H. Marco Jansen, Simone de Haij, Frank J. Beurskens, Cees E. van der Poel, Lisette Bevaart, Maaike Nederend, Josée Golay, Jan G.J. van de Winkel, Paul W.H.I. Parren, Jeanette H.W. Leusen   +10 more
doaj   +1 more source

Enhanced CDC of B cell chronic lymphocytic leukemia cells mediated by rituximab combined with a novel anti-complement factor H antibody. [PDF]

PLoS ONE, 2017
Rituximab therapy for B cell chronic lymphocytic leukemia (B-CLL) has met with mixed success. Among several factors to which resistance can be attributed is failure to activate complement dependent cytotoxicity (CDC) due to protective complement ...
Mark T Winkler, Ryan T Bushey, Elizabeth B Gottlin, Michael J Campa, Eross S Guadalupe, Alicia D Volkheimer, J Brice Weinberg, Edward F Patz   +7 more
doaj   +1 more source

Applicability of Traditional In Vitro Toxicity Tests for Assessing Adverse Effects of Monoclonal Antibodies: A Case Study of Rituximab and Trastuzumab

Antibodies, 2018
Monoclonal antibody (mAb) therapeutics have a promising outlook within the pharmaceutical industry having made positive strides in both research and development as well as commercialisation, however this development has been hampered by manufacturing ...
Arathi Kizhedath, Simon Wilkinson, Jarka Glassey   +2 more
doaj   +1 more source

The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs

Antibodies, 2020
Unconjugated anti-cancer IgG1 monoclonal antibodies (mAbs) activate antibody-dependent cellular cytotoxicity (ADCC) by natural killer (NK) cells and antibody-dependent cellular phagocytosis (ADCP) by macrophages, and these activities are thought to be ...
Josée Golay, Ronald P. Taylor
doaj   +1 more source

Luminex-Based Donor-Specific antibody crossmatching for renal transplant: A 3-Year experience in South India

Global Journal of Transfusion Medicine, 2018
Introduction: Although CDC has been the gold standard for many years, this assay is certainly not perfect and its use is associated with several problems. The Luminex anti-HLA antibody detection assay is reportedly more sensitive and specific. One of the
Ankit Mathur, Samrat Thapa, Latha Jagannathan   +2 more
doaj   +1 more source

The Comprehensive Live Cell-Based Cytotoxicity Assay for Monitoring Disease Activity and Guiding Rescue Therapy in Acute Attacks of NMOSD. [PDF]

Ann Clin Transl Neurol
ABSTRACT Objective Neuromyelitis optica spectrum disorder (NMOSD) is a devastating neurological disease that lacks serological biomarkers that can accurately reflect disease activity. We established a live cell‐based assay (LCBA) using serum with endogenous complement to quantify the overall cytotoxicity, offering a novel functional tool for monitoring
Xu X, Ding J, Du Y, Luo G, Li J, Liu R, Xu X, Li X, Li M, Jiang W, Yang C.   +10 more
europepmc   +2 more sources